Four-year data from the BICSTaR study confirms Biktarvy's sustained efficacy and safety in diverse HIV patients, showing high rates of virologic suppression and improved patient outcomes.
Gilead's PURPOSE 2 trial results show lenacapavir's potential as a twice-yearly HIV prevention option for cisgender men and gender-diverse individuals.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.